Molecular Glue Degraders Promote Lysosomal Degradation of APP as a Therapeutic Strategy for Alzheimer’s Disease
- Enhancing targeted degradation of amyloid precursor protein (APP) by leveraging CAPRIN1-dependent lysosomal pathways to advance therapeutic strategies for Alzheimer’s disease
- Restoring neuronal stability through selective molecular glue modulation of APP processing, reducing amyloid accumulation and neurotoxicity
- Accelerating translational drug development using AI-assisted ligand and structure-based design to create blood-brain barrier–permeable APP degraders for Alzheimer’s therapy